Mean (SD) antibiotic use in the azithromycin and placebo groups during the study
| Azithromycin | Placebo | Count ratio azithromycin/placebo estimate(95% CI) | |
|---|---|---|---|
| SD, standard deviation; CI, confidence interval; PA, Pseudomonas aeruginosa; IV, intravenous; NS, not significant. | |||
| Sample sizes in the azithromycin and placebo groups were, respectively, 40 and 42 for the total population, 31 and 32 for the patients not infected with PA, and 9 and 10 for patients infected with PA. | |||
| Oral antibiotics | |||
| Number of courses | |||
| Total population | 2.1 (0.4) | 3.8 (0.5) | 0.55 (0.36 to 0.85), p<0.01 |
| Patients not infected with PA | 2.1 (0.4) | 3.6 (0.5) | 0.59 (0.36 to 0.98), p<0.05 |
| Patients infected with PA | 2.2 (0.9) | 4.5 (1.2) | 0.49 (0.20 to 1.24), NS |
| Cumulative days of treatment | |||
| Total population | 62 (13) | 74 (13) | 0.85 (0.50 to 1.44), NS |
| Patients not infected with PA | 67 (15) | 67 (15) | 1.00 (0.54 to 1.88), NS |
| Patients infected with PA | 53 (23) | 96 (29) | 0.56 (0.20 to 1.53), NS |
| IV antibiotics | |||
| Number of courses | |||
| Total population | 0.8 (0.2) | 1.6 (0.4) | 0.48 (0.22 to 1.02), NS |
| Patients not infected with PA | 0.4 (0.2) | 0.5 (0.2) | 0.80 (0.30 to 2.13), NS |
| Patients infected with PA | 2.1 (0.8) | 5.2 (1.2) | 0.41 (0.17 to 0.96), p<0.05 |
| Cumulative days of treatment | |||
| Total population | 12 (4) | 24 (5) | 0.51 (0.24 to 1.09), NS |
| Patients not infected with PA | 6 (2) | 6 (2) | 0.95 (0.36 to 2.52), NS |
| Patients infected with PA | 34 (13) | 81 (19) | 0.42 (0.18 to 1.00), p = 0.05 |